Author

E. Dominguez-Vega

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

M. Wuhrer· 3 shared A. Resemann· 1 shared C. Bloechl· 1 shared C. Gstoettner· 1 shared C. Gstottner· 1 shared D. L. E. Vergoossen· 1 shared D. Suckau· 1 shared E. M. Stork· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. Wuhrer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Fc proteoforms of ACPA IgG discriminate autoimmune responses in plasma and synovial fluid of rheumatoid arthritis patients and associate with disease activity

C. Bloechl, E. M. Stork, H. U. Scherer, R. E. M. Toes, M. Wuhrer, E. Dominguez-Vega

The paper identifies Fc proteoforms of ACPA IgG that distinguish autoimmune responses in RA patients and correlate with disease activity.

bioRxiv · Apr 4, 2024Immunology

Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells

C. Gstoettner, T. Zhang, A. Resemann, S. Ruben, S. Pengelley, D. Suckau, T. Welsink, M. Wuhrer, E. Dominguez-Vega

This study characterizes SARS-CoV-2 RBDs produced in CHO and HEK293 cells, revealing distinct glycosylation patterns and confirming O-glycosylation at T323, with comparable functional binding properties.

bioRxiv · Feb 23, 2021Biochemistry

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis

D. L. E. Vergoossen, J. J. Plomp, C. Gstottner, Y. E. Fillie-Grijpma, R. Augustinus, R. Verpalen, M. Wuhrer, P. W. H. I. Parren, E. Dominguez-Vega, S. M. van der Maarel, J. J. Verschuuren, M. G. Huijbers

This study shows that monovalent anti-MuSK IgG4 antibodies enhance pathogenicity in myasthenia gravis compared to their bivalent form.

bioRxiv · Sep 24, 2020Immunology